When Is Tysabri PML Risk Typically Evaluated?
Latest update (2026-07)
- Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
General Health Context and Occupational Exposure Considerations
If you or a loved one is taking Tysabri, you may wonder when doctors typically evaluate the risk of progressive multifocal leukoencephalopathy (PML). This question reflects a long-standing focus in pharmacovigilance on understanding and communicating the balance between therapeutic benefit and serious adverse events. This page reviews current research on PML risk assessment and screening recommendations.
Tysabri and PML: The Established Causal Link
Tysabri (natalizumab) is a monoclonal antibody used as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. The drug's prescribing information contains a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial data and postmarketing surveillance. The mechanism linking Tysabri to PML involves the drug's pharmacological action. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs normal immune surveillance. The JC virus, which is latent in many individuals, can reactivate and cause lytic infection of oligodendrocytes in the brain when immune control is compromised. The resulting demyelination leads to the clinical syndrome of PML. Clinical trial data documented PML cases in patients receiving Tysabri. In multiple sclerosis trials, two cases of PML occurred among 1869 patients treated for a median of 120 weeks. Both patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In Crohn's disease trials, one case occurred after eight doses among 1043 patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases established the causal relationship between Tysabri and PML.
Risk Factors and Temporal Association
Three risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration especially beyond two years, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Anti-JCV antibody status indicates prior exposure to the virus. Patients who are seropositive have a higher risk for developing PML. Treatment duration beyond two years further increases risk. Prior immunosuppressant use compounds the risk by further compromising immune function. The timeline between Tysabri exposure and PML onset varies. In clinical trials, PML occurred after varying durations of treatment. The two multiple sclerosis patients developed PML after a median of 120 weeks of treatment, while the Crohn's disease patient developed PML after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Postmarketing experience has shown that PML can occur at any time during treatment, but risk increases with longer exposure. The adequacy of warnings regarding Tysabri and PML is addressed through multiple regulatory mechanisms. The boxed warning clearly states that Tysabri increases PML risk and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information requires healthcare professionals to consider risk factors in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Monitoring requirements mandate that patients be observed for any new sign or symptom suggestive of PML, and dosing should be withheld immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Causation Assessment for Affected Patients
For affected patients, causation considerations involve the established causal link between Tysabri and PML. The drug's labeling explicitly states that PML has occurred in patients who have received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The presence of identified risk factors—anti-JCV antibodies, treatment duration, and prior immunosuppressant use—can help assess individual patient risk. However, PML can occur even in patients without all risk factors. The clinical presentation of PML includes progressive neurological deficits such as weakness, sensory loss, visual disturbances, and cognitive decline. Diagnosis is confirmed by brain MRI showing demyelinating lesions and detection of JCV DNA in cerebrospinal fluid. The timeline between Tysabri exposure and PML onset is relevant for causation assessment. In clinical trials, PML occurred after months to years of treatment. The two multiple sclerosis cases occurred after a median of 120 weeks, while the Crohn's disease case occurred after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This temporal relationship supports causation. PML can also occur after Tysabri discontinuation due to immune reconstitution inflammatory syndrome, which can unmask latent infection. In summary, the evidence establishes that Tysabri causes PML through impairment of immune surveillance in the central nervous system. The drug's labeling provides clear warnings about this risk, identifies specific risk factors, and mandates monitoring and restricted distribution. For affected patients, the causal relationship is supported by clinical trial data, identified risk factors, and temporal association between exposure and disease onset.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the causal relationship between Tysabri and PML?
Clinical trial data and postmarketing surveillance have established that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML). The drug's boxed warning states that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
What are the risk factors for developing PML while on Tysabri?
Three main risk factors have been identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
How is PML diagnosed in patients with Tysabri exposure?
Diagnosis is confirmed by brain MRI showing demyelinating lesions and detection of JC virus DNA in cerebrospinal fluid. Clinical presentation includes progressive neurological deficits such as weakness, sensory loss, visual disturbances, and cognitive decline.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
- Tysabri Progressive Multifocal Leukoencephalopathy lawsuit settlement criteria
- Tysabri linked to Progressive Multifocal Leukoencephalopathy
- FDA warning Tysabri Progressive Multifocal Leukoencephalopathy
- Statute of limitations for Tysabri in Michigan
- Statute of limitations for Tysabri in Florida
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.